Inicio>>TP-238 (hydrochloride)

TP-238 (hydrochloride)

Catalog No.GC45640

TP-238 (clorhidrato) es una sonda CECR2/BPTF dual potente y selectiva con valores IC50 de 30 nM y 350 nM, respectivamente. TP-238 (clorhidrato) también inhibe BRD9 con un pIC50 de 5,9 y es menos activo frente a otras 338 quinasas.

Products are for research use only. Not for human use. We do not sell to patients.

TP-238 (hydrochloride) Chemical Structure

Cas No.: 2415263-05-5

Tamaño Precio Disponibilidad Cantidad
1mg
131,00 $
Disponible
5mg
391,00 $
Disponible
10mg
716,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TP-238 is a chemical probe for the bromodomains of cat eye syndrome chromosome region, candidate 2 (CECR2) and bromodomain PHD finger transcription factor (BPTF). It has on-target biochemical activity with CECR2 when used at concentrations ranging from 10 to 30 nM and with BPTF at concentrations ranging from 100 to 350 nM. It is selective for the CECR2 and BPTF bromodomains over BRD9 (IC50 = 1.4 μM), as well as over a panel of 338 kinases at 1 μM. TP-238 binds to CECR2 and BPTF with KD values of 10 and 120 nM, respectively, in an isothermal titration calorimetry (ITC) assay and IC50 values of 30 and 350 nM, respectively, in an AlphaScreen• assay. See the Structural Genomics Consortium (SGC) website for more information.

Reseñas

Review for TP-238 (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TP-238 (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.